COVID-19 Vaccine Efficacy in Participants With Weakened Immune Systems From 4 Randomized Controlled Trials.
Amy C Sherman, Jessica Tuan, Valeria D Cantos, Oladunni Adeyiga, Scott Mahoney, Ana M Ortega-Villa, Amy Tillman, Jennifer Whitaker, Amanda S Woodward Davis, Brett Leav, Ian Hirsch, Jerald Sadoff, Lisa M Dunkle, Peter B Gilbert, Holly E Janes, James G Kublin, Paul A Goepfert, Karen Kotloff, Nadine Rouphael, Ann R Falsey, Hana M El Sahly, Magdalena E Sobieszczyk, Yunda Huang, Kathleen M Neuzil, Lawrence Corey, Beatriz Grinsztejn, Glenda Gray, Martha Nason, Lindsey R Baden, Cynthia L Gay
Clin Infect Dis 79(2) 364-374
摘要
摘要
BACKGROUND: Although the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines are highly efficacious at preventing severe disease in the general population, current data are lacking regarding vaccine efficacy (VE) for individuals with mild immunocompromising conditions. METHODS: A post hoc, cross-protocol analysis of participant-level data from the blinded phase of four randomized, placebo-controlled, coronavirus disease 2019 (COVID-19) vaccine phase 3 trials (Moderna, AstraZeneca, Janssen, and Novavax) was performed. We defined a "tempered immune system" (TIS) variable via a consensus panel based on medical history and medications to determine VE against symptomatic and severe COVID-19 cases in TIS participants versus non-TIS individuals starting at 14 days after completion of the primary series through the blinded phase for each of the 4 trials. An analysis of participants living with well-controlled human immunodeficiency virus was conducted using the same methods. RESULTS: A total of 3852/30 351 (12.7%) Moderna participants, 3088/29 868 (10.3%) Novavax participants, 3549/32 380 (11.0%) AstraZeneca participants, and 5047/43 788 (11.5%) Janssen participants were identified as having a TIS. Most TIS conditions (73.9%) were due to metabolism and nutritional disorders. Vaccination (vs placebo) significantly reduced the likelihood of symptomatic and severe COVID-19 for all participants for each trial. VE was not significantly different for TIS participants versus non-TIS for either symptomatic or severe COVID-19 for each trial, nor was VE significantly different in the symptomatic endpoint for participants with human immunodeficiency virus. CONCLUSIONS: For individuals with mildly immunocompromising conditions, there is no evidence of differences in VE against symptomatic or severe COVID-19 compared with those with non-TIS in the 4 COVID-19 vaccine randomized controlled efficacy trials.
KM 提取结果
0 个 Figure · 0 个 KM 面板